Amarin defends Vascepa's CV-prevention data against supplement makers eager to cash in

Amarin spent years, millions of dollars and a lot of willpower proving its fish oil-based drug Vascepa really could cut cardiovascular risks. To make that effort pay off, it needs to keep that proof to itself—and it's got lawyers "on speed dial" to do just that.